Study details
Enrolling now
MMA Embolization for Refractory Chronic Migraine
Cerenovus, Part of DePuy Synthes Products, Inc.
NCT IDNCT06735833ClinicalTrials.gov data as of Apr 2026
Target enrollment
50
Study length
about 3.7 years
Ages
18–65
Locations
9 sites in AZ, CA, CT +4
What this study is about
Researchers are testing a new way to treat severe migraines that haven't responded to other treatments. The treatment involves blocking blood flow in the middle meningeal artery using a device. The trial will last about 1346 days and aims to enroll around 50 adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use Middle Meningeal Artery embolization
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Change from baseline, in number of migraine days
Secondary: Change from baseline in migraine days frequency
Body systems
Neurology